Breaking News Instant updates and real-time market news.

DVA

DaVita

$97.37 /

-4.615 (-4.53%)

06:06
11/29/21
11/29
06:06
11/29/21
06:06

DaVita study indicates effectiveness of COVID-19 vaccines in dialysis patients

Dialysis patients who received mRNA COVID-19 vaccines had a lower risk of COVID-19 diagnosis post-vaccination and were less likely to be hospitalized or die following breakthrough infection than unvaccinated patients, according to a DaVita Clinical Research study published online ahead of print by the Journal of the American Society of Nephrology. To assess COVID-19 vaccine effectiveness in this patient population, researchers evaluated electronic health records of 35,206 DaVita dialysis patients vaccinated with Pfizer/BioNTech or Moderna vaccines between January 1 and February 25. These patients were matched to unvaccinated controlled groups and followed over time to observe future COVID-19 infections and related clinical outcomes. Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing COVID-19 infections, respectively. The study indicated that vaccinated dialysis patients who experienced a breakthrough COVID-19 infection were also less likely to be hospitalized or die from COVID-19 as compared to unvaccinated patients diagnosed with COVID-19. In addition, among vaccinated dialysis patients, SARS-CoV-2 antibodies were detected in rates similar to those seen in the broader Phase III clinical trials.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Leap Therapeutics to present new data from DisTinGuish Study of DKN-01 at ASCO » 20:56
01/18/22
01/18
20:56
01/18/22
20:56
LPTX

Leap Therapeutics

$2.74 /

-0.095 (-3.35%)

Leap Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LPTX Leap Therapeutics
$2.74 /

-0.095 (-3.35%)

LPTX Leap Therapeutics
$2.74 /

-0.095 (-3.35%)

12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
10/04/21 Mizuho
Leap Therapeutics initiated with a Buy at Mizuho
09/19/21 Piper Sandler
Piper Sandler keeps Overweight on Leap Therapeutics, ups target to $5
09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
LPTX Leap Therapeutics
$2.74 /

-0.095 (-3.35%)

  • 22
    Sep
LPTX Leap Therapeutics
$2.74 /

-0.095 (-3.35%)

LPTX Leap Therapeutics
$2.74 /

-0.095 (-3.35%)

Initiation
Compass Therapeutics initiated with a Buy at B. Riley » 20:38
01/18/22
01/18
20:38
01/18/22
20:38
CMPX

Compass Therapeutics

$2.75 /

+ (+0.00%)

B. Riley analyst Justin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CMPX Compass Therapeutics
$2.75 /

+ (+0.00%)

CMPX Compass Therapeutics
$2.75 /

+ (+0.00%)

12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
12/22/21 Raymond James
Compass Therapeutics initiated with an Outperform at Raymond James
12/22/21 Raymond James
Compass Therapeutics initiated with an Outperform at Raymond James
12/20/21 SVB Leerink
SVB Leerink bullish on Compass Therapeutics, initiates with an Outperform
  • 02
    Nov
CMPX Compass Therapeutics
$2.75 /

+ (+0.00%)

Hot Stocks
Whitestone REIT terminates CEO James Mastandrea for cause » 20:37
01/18/22
01/18
20:37
01/18/22
20:37
WSR

Whitestone REIT

$10.06 /

-0.135 (-1.32%)

Whitestone REIT…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WSR Whitestone REIT
$10.06 /

-0.135 (-1.32%)

Upgrade
Commercial Metals upgraded to Overweight from Sector Weight at KeyBanc » 20:31
01/18/22
01/18
20:31
01/18/22
20:31
CMC

Commercial Metals

$36.49 /

-1.42 (-3.75%)

KeyBanc analyst Philip…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CMC Commercial Metals
$36.49 /

-1.42 (-3.75%)

CMC Commercial Metals
$36.49 /

-1.42 (-3.75%)

01/11/22 BMO Capital
Commercial Metals price target raised to $40 from $34 at BMO Capital
12/29/21 Citi
Commercial Metals price target raised to $38 from $34 at Citi
12/10/21
Fly Intel: Top five analyst upgrades
12/10/21 JPMorgan
Commercial Metals upgraded to Overweight from Neutral at JPMorgan
CMC Commercial Metals
$36.49 /

-1.42 (-3.75%)

CMC Commercial Metals
$36.49 /

-1.42 (-3.75%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
01/18/22
01/18
20:25
01/18/22
20:25
UNH

UnitedHealth

$461.08 /

-7.59 (-1.62%)

, BAC

Bank of America

$46.36 /

-1.57 (-3.28%)

, PG

Procter & Gamble

$156.86 /

-2.94 (-1.84%)

, MS

Morgan Stanley

$94.28 /

-4.6 (-4.65%)

, USB

U.S. Bancorp

$62.20 /

-1.045 (-1.65%)

, STT

State Street

$101.06 /

-2.73 (-2.63%)

, FAST

Fastenal

$58.42 /

-0.79 (-1.33%)

, CFG

Citizens Financial

$55.67 /

-0.69 (-1.22%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include UnitedHealth (UNH), consensus $4.31... Bank of America (BAC), consensus 76c... Procter & Gamble (PG), consensus $1.65... Morgan Stanley (MS), consensus $38.65... U.S. Bancorp (USB), consensus $1.10... State Street (STT), consensus $1.88... Fastenal (FAST), consensus 38c... Citizens Financial (CFG), consensus $1.13.

ShowHide Related Items >><<
UNH UnitedHealth
$461.08 /

-7.59 (-1.62%)

BAC Bank of America
$46.36 /

-1.57 (-3.28%)

PG Procter & Gamble
$156.86 /

-2.94 (-1.84%)

MS Morgan Stanley
$94.28 /

-4.6 (-4.65%)

USB U.S. Bancorp
$62.20 /

-1.045 (-1.65%)

STT State Street
$101.06 /

-2.73 (-2.63%)

FAST Fastenal
$58.42 /

-0.79 (-1.33%)

CFG Citizens Financial
$55.67 /

-0.69 (-1.22%)

UNH UnitedHealth
$461.08 /

-7.59 (-1.62%)

01/11/22 Bernstein
UnitedHealth price target raised to $564 from $508 at Bernstein
01/10/22 Edward Jones
UnitedHealth initiated with a Buy at Edward Jones
01/05/22 Truist
UnitedHealth price target raised to $575 from $520 at Truist
01/04/22 Piper Sandler
Nevro shares should rally on UnitedHealthcare coverage, says Piper Sandler
BAC Bank of America
$46.36 /

-1.57 (-3.28%)

01/12/22 Citi
Citi opens '30-Day Positive Catalyst Watch' on Bank of America
01/11/22 Piper Sandler
Bank of America the large cap bank stock to own for 2022, says Piper Sandler
01/06/22 JPMorgan
Bank of America price target raised to $52.50 from $50 at JPMorgan
01/05/22 Societe Generale
Bank of America downgraded to Hold at Societe Generale on expensive valuation
PG Procter & Gamble
$156.86 /

-2.94 (-1.84%)

10/20/21 Deutsche Bank
Procter & Gamble price target lowered to $160 from $163 at Deutsche Bank
10/19/21 Stifel
Procter & Gamble Q1 results 'solid' amid added cost headwinds, says Stifel
10/05/21
Fly Intel: Top five analyst initiations
10/05/21 BofA
Procter & Gamble reinitiated with a Buy at BofA
MS Morgan Stanley
$94.28 /

-4.6 (-4.65%)

01/03/22 Barclays
Morgan Stanley price target raised to $123 from $110 at Barclays
12/03/21
Fly Intel: Top five analyst upgrades
12/03/21 Citi
Morgan Stanley upgraded to Buy from Neutral at Citi
10/18/21 Citi
Morgan Stanley price target raised to $105 from $100 at Citi
USB U.S. Bancorp
$62.20 /

-1.045 (-1.65%)

01/03/22 Barclays
U.S. Bancorp downgraded to Equal Weight from Overweight at Barclays
12/09/21 UBS
UBS starts 'not so boring' U.S. Bancorp at Buy
12/09/21 UBS
U.S. Bancorp initiated with a Buy at UBS
11/29/21 Stephens
Stephens downgrades U.S. Bancorp to Equal Weight on outsized travel exposure
STT State Street
$101.06 /

-2.73 (-2.63%)

01/10/22 Keefe Bruyette
BNY Mellon downgraded to Market Perform from Outperform at Keefe Bruyette
01/03/22 Keefe Bruyette
Apollo long, Rocket short amid KBW's 13 best ideas for 2022
01/03/22 Barclays
State Street price target raised to $130 from $110 at Barclays
12/17/21 Deutsche Bank
State Street price target raised to $133 from $121 at Deutsche Bank
FAST Fastenal
$58.42 /

-0.79 (-1.33%)

12/07/21 Loop Capital
Fastenal price target raised to $57 from $53 at Loop Capital
12/07/21 Baird
Fastenal price target raised to $62 from $59 at Baird
10/08/21 Wells Fargo
Wells downgrades Fastenal to Underweight on 'multiple emerging risks'
10/08/21 Wells Fargo
Fastenal downgraded to Underweight from Equal Weight at Wells Fargo
CFG Citizens Financial
$55.67 /

-0.69 (-1.22%)

01/13/22 UBS
Citizens Financial initiated with a Neutral at UBS
01/13/22 Morgan Stanley
NatWest Group, SVB Financial added as top bank picks at Morgan Stanley
01/11/22 Citi
Citizens Financial upgraded to Buy with $65 target at Citi
01/11/22 Citi
Citizens Financial upgraded to Buy from Neutral at Citi
UNH UnitedHealth
$461.08 /

-7.59 (-1.62%)

BAC Bank of America
$46.36 /

-1.57 (-3.28%)

PG Procter & Gamble
$156.86 /

-2.94 (-1.84%)

MS Morgan Stanley
$94.28 /

-4.6 (-4.65%)

USB U.S. Bancorp
$62.20 /

-1.045 (-1.65%)

STT State Street
$101.06 /

-2.73 (-2.63%)

FAST Fastenal
$58.42 /

-0.79 (-1.33%)

CFG Citizens Financial
$55.67 /

-0.69 (-1.22%)

  • 10
    Sep
UNH UnitedHealth
$461.08 /

-7.59 (-1.62%)

BAC Bank of America
$46.36 /

-1.57 (-3.28%)

PG Procter & Gamble
$156.86 /

-2.94 (-1.84%)

MS Morgan Stanley
$94.28 /

-4.6 (-4.65%)

USB U.S. Bancorp
$62.20 /

-1.045 (-1.65%)

STT State Street
$101.06 /

-2.73 (-2.63%)

CFG Citizens Financial
$55.67 /

-0.69 (-1.22%)

UNH UnitedHealth
$461.08 /

-7.59 (-1.62%)

BAC Bank of America
$46.36 /

-1.57 (-3.28%)

PG Procter & Gamble
$156.86 /

-2.94 (-1.84%)

MS Morgan Stanley
$94.28 /

-4.6 (-4.65%)

USB U.S. Bancorp
$62.20 /

-1.045 (-1.65%)

STT State Street
$101.06 /

-2.73 (-2.63%)

FAST Fastenal
$58.42 /

-0.79 (-1.33%)

CFG Citizens Financial
$55.67 /

-0.69 (-1.22%)

UNH UnitedHealth
$461.08 /

-7.59 (-1.62%)

BAC Bank of America
$46.36 /

-1.57 (-3.28%)

PG Procter & Gamble
$156.86 /

-2.94 (-1.84%)

MS Morgan Stanley
$94.28 /

-4.6 (-4.65%)

USB U.S. Bancorp
$62.20 /

-1.045 (-1.65%)

CFG Citizens Financial
$55.67 /

-0.69 (-1.22%)

Downgrade
Coca-Cola Femsa downgraded to Neutral from Buy at Goldman Sachs » 20:11
01/18/22
01/18
20:11
01/18/22
20:11
KOF

Coca-Cola Femsa

$55.07 /

-0.64 (-1.15%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KOF Coca-Cola Femsa
$55.07 /

-0.64 (-1.15%)

12/20/21 Citi
Coca-Cola Femsa upgraded to Buy from Neutral at Citi
08/13/21 Goldman Sachs
Coca-Cola Femsa initiated with a Buy at Goldman Sachs
08/03/21 Barclays
Coca-Cola Femsa price target raised to $55 from $50 at Barclays
07/27/21 Scotiabank
Coca-Cola Femsa upgraded to Outperform from Sector Perform at Scotiabank
Hot Stocks
Rackspace Technology to acquire Just Analytics » 20:09
01/18/22
01/18
20:09
01/18/22
20:09
RXT

Rackspace Technology

$13.01 /

+0.21 (+1.64%)

, MSFT

Microsoft

$303.00 /

-7.01 (-2.26%)

Rackspace Technology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RXT Rackspace Technology
$13.01 /

+0.21 (+1.64%)

MSFT Microsoft
$303.00 /

-7.01 (-2.26%)

RXT Rackspace Technology
$13.01 /

+0.21 (+1.64%)

10/29/21 Credit Suisse
Rackspace Technology assumed with an Outperform at Credit Suisse
08/17/21
Fly Intel: Top five analyst downgrades
08/17/21 JPMorgan
Rackspace downgraded to Neutral on restructuring at JPMorgan
08/17/21 JPMorgan
Rackspace Technology downgraded to Neutral from Overweight at JPMorgan
MSFT Microsoft
$303.00 /

-7.01 (-2.26%)

16:38 Today Truist
Activision Blizzard downgraded to Hold from Buy at Truist
14:30 Today Stifel
Stifel sees several reasons to like Microsoft's Activision Blizzard deal
14:19 Today Stifel
Activision Blizzard deal shines positive light on video game group, says Stifel
12:13 Today Piper Sandler
Unity an indirect beneficiary of Microsoft/Activision deal, says Piper Sandler
RXT Rackspace Technology
$13.01 /

+0.21 (+1.64%)

MSFT Microsoft
$303.00 /

-7.01 (-2.26%)

MSFT Microsoft
$303.00 /

-7.01 (-2.26%)

RXT Rackspace Technology
$13.01 /

+0.21 (+1.64%)

MSFT Microsoft
$303.00 /

-7.01 (-2.26%)

MSFT Microsoft
$303.00 /

-7.01 (-2.26%)

Upgrade
Arcos Dorados upgraded to Buy from Neutral at Goldman Sachs » 20:06
01/18/22
01/18
20:06
01/18/22
20:06
ARCO

Arcos Dorados

$5.41 /

-0.065 (-1.19%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ARCO Arcos Dorados
$5.41 /

-0.065 (-1.19%)

09/20/21 BofA
Arcos Dorados downgraded to Neutral from Buy at BofA
07/02/21 JPMorgan
Arcos Dorados assumed with an Overweight at JPMorgan
04/22/21 Goldman Sachs
Arcos Dorados initiated with a Neutral at Goldman Sachs
01/28/21 Bradesco BBI
Arcos Dorados downgraded to Neutral from Outperform at Bradesco BBI
ARCO Arcos Dorados
$5.41 /

-0.065 (-1.19%)

On The Fly
Fly Intel: After-Hours Movers » 19:32
01/18/22
01/18
19:32
01/18/22
19:32
NCBS

Nicolet Bankshares

$87.28 /

-0.62 (-0.71%)

, JBHT

J.B. Hunt

$200.56 /

-1.48 (-0.73%)

, SOFI

SoFi Technologies

$12.04 /

-1.16 (-8.79%)

, PNFP

Pinnacle Financial

$107.92 /

-2.04 (-1.86%)

, GRAB

Grab Holdings

$5.55 /

-0.495 (-8.19%)

, RVNC

Revance

$14.31 /

-1.045 (-6.81%)

, OESX

Orion Energy

$4.00 /

-0.23 (-5.44%)

, FULT

Fulton Financial

$18.84 /

-0.06 (-0.32%)

, IBKR

Interactive Brokers

$71.95 /

-2.84 (-3.80%)

ShowHide Related Items >><<
NCBS Nicolet Bankshares
$87.28 /

-0.62 (-0.71%)

JBHT J.B. Hunt
$200.56 /

-1.48 (-0.73%)

SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

PNFP Pinnacle Financial
$107.92 /

-2.04 (-1.86%)

GRAB Grab Holdings
$5.55 /

-0.495 (-8.19%)

RVNC Revance
$14.31 /

-1.045 (-6.81%)

OESX Orion Energy
$4.00 /

-0.23 (-5.44%)

FULT Fulton Financial
$18.84 /

-0.06 (-0.32%)

IBKR Interactive Brokers
$71.95 /

-2.84 (-3.80%)

NCBS Nicolet Bankshares
$87.28 /

-0.62 (-0.71%)

09/08/21 Piper Sandler
Nicolet Bankshares upgraded to Overweight from Neutral at Piper Sandler
06/28/21
Fly Intel: Top five analyst upgrades
06/28/21 Stephens
Nicolet Bankshares upgraded to Overweight on recent deals at Stephens
06/28/21 Stephens
Nicolet Bankshares upgraded to Overweight from Equal Weight at Stephens
JBHT J.B. Hunt
$200.56 /

-1.48 (-0.73%)

01/14/22 Barclays
J.B. Hunt price target raised to $212 from $195 at Barclays
01/12/22 Citi
J.B. Hunt price target raised to $230 from $205 at Citi
01/10/22 Wells Fargo
J.B. Hunt price target raised to $233 from $216 at Wells Fargo
01/04/22 Stephens
J.B. Hunt price target raised to $225 from $212 at Stephens
SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

16:48 Today Wedbush
Wedbush starts SoFi at Outperform on 'strong' growth outlook
16:16 Today Wedbush
SoFi Technologies initiated with an Outperform at Wedbush
06:55 Today Mizuho
SoFi Technologies price target lowered to $17 from $30 at Mizuho
04:48 Today Goldman Sachs
SoFi Technologies initiated with a Neutral at Goldman Sachs
PNFP Pinnacle Financial
$107.92 /

-2.04 (-1.86%)

11/11/21 Wells Fargo
Pinnacle Financial price target raised to $145 from $120 at Wells Fargo
10/14/21 Truist
Pinnacle Financial price target raised to $120 from $105 at Truist
10/14/21 JPMorgan
Pinnacle Financial price target raised to $120 from $113 at JPMorgan
07/22/21 Truist
Pinnacle Financial price target raised to $105 from $100 at Truist
GRAB Grab Holdings
$5.55 /

-0.495 (-8.19%)

16:16 Today Loop Capital
Grab Holdings initiated with a Buy at Loop Capital
16:13 Today Loop Capital
Grab Holdings initiated with a Buy at Loop Capital
12/30/21 Jefferies
Jefferies starts 'multi-year story' Grab with Buy, $10.50 target
12/30/21 Jefferies
Grab Holdings initiated with a Buy at Jefferies
RVNC Revance
$14.31 /

-1.045 (-6.81%)

10/26/21 Barclays
Revance price target lowered to $22 from $33 at Barclays
10/25/21 Wells Fargo
Revance downgraded to Equal Weight from Overweight at Wells Fargo
10/25/21 Wells Fargo
Revance downgraded to Equal Weight from Overweight at Wells Fargo
10/18/21 Needham
Revance price target lowered to $25 from $45 at Needham
OESX Orion Energy
$4.00 /

-0.23 (-5.44%)

11/10/21 B. Riley
Orion Energy downgraded to Neutral from Buy at B. Riley
08/05/21 B. Riley
Orion Energy price target lowered to $8.50 from $10.50 at B. Riley
08/04/21 Roth Capital
Orion Energy price target lowered to $5 from $7 at Roth Capital
06/02/21
Fly Intel: Top five analyst downgrades
FULT Fulton Financial
$18.84 /

-0.06 (-0.32%)

04/07/21 Raymond James
Fulton Financial downgraded to Market Perform from Outperform at Raymond James
IBKR Interactive Brokers
$71.95 /

-2.84 (-3.80%)

12/15/21 BofA
BofA starts Interactive Brokers at Buy, says has 'key' advantage in tech R&D
12/15/21 BofA
Interactive Brokers initiated with a Buy at BofA
04/21/21 Credit Suisse
Interactive Brokers price target raised to $110 from $92 at Credit Suisse
04/09/21 Jefferies
Charles Schwab price target raised to $76 from $70 at Jefferies
NCBS Nicolet Bankshares
$87.28 /

-0.62 (-0.71%)

JBHT J.B. Hunt
$200.56 /

-1.48 (-0.73%)

SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

PNFP Pinnacle Financial
$107.92 /

-2.04 (-1.86%)

RVNC Revance
$14.31 /

-1.045 (-6.81%)

OESX Orion Energy
$4.00 /

-0.23 (-5.44%)

FULT Fulton Financial
$18.84 /

-0.06 (-0.32%)

IBKR Interactive Brokers
$71.95 /

-2.84 (-3.80%)

  • 16
    Nov
JBHT J.B. Hunt
$200.56 /

-1.48 (-0.73%)

GRAB Grab Holdings
$5.55 /

-0.495 (-8.19%)

IBKR Interactive Brokers
$71.95 /

-2.84 (-3.80%)

JBHT J.B. Hunt
$200.56 /

-1.48 (-0.73%)

SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

PNFP Pinnacle Financial
$107.92 /

-2.04 (-1.86%)

GRAB Grab Holdings
$5.55 /

-0.495 (-8.19%)

RVNC Revance
$14.31 /

-1.045 (-6.81%)

IBKR Interactive Brokers
$71.95 /

-2.84 (-3.80%)

NCBS Nicolet Bankshares
$87.28 /

-0.62 (-0.71%)

JBHT J.B. Hunt
$200.56 /

-1.48 (-0.73%)

SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

PNFP Pinnacle Financial
$107.92 /

-2.04 (-1.86%)

GRAB Grab Holdings
$5.55 /

-0.495 (-8.19%)

FULT Fulton Financial
$18.84 /

-0.06 (-0.32%)

IBKR Interactive Brokers
$71.95 /

-2.84 (-3.80%)

Upgrade
Siltronic upgraded to Buy from Hold at Jefferies » 19:13
01/18/22
01/18
19:13
01/18/22
19:13
SSLLF

Siltronic

$144.11 /

-9.5491 (-6.21%)

Jefferies analyst…

Jefferies analyst Constantin Hesse upgraded Siltronic to Buy from Hold with a EUR 160 price target. The analyst said the recent share price correction presents an attractive entry point. Hesse added that he expects Siltronic's solid sales momentum to continue into FY22, driven by the continued solid demand for semiconductors.

ShowHide Related Items >><<
SSLLF Siltronic
$144.11 /

-9.5491 (-6.21%)

05:35 Today Oddo BHF
Siltronic upgraded to Outperform from Neutral at Oddo BHF
02/02/21 Berenberg
Siltronic price target raised to EUR 145 from EUR 125 at Berenberg
01/26/21 Deutsche Bank
Siltronic downgraded to Hold from Buy at Deutsche Bank
01/26/21 Stifel
Siltronic downgraded to Hold from Buy at Stifel
Hot Stocks
EQRx says sugemalimab shows statistically significant OS benefit » 19:01
01/18/22
01/18
19:01
01/18/22
19:01
EQRX

EQRx, Inc.

$6.27 /

-0.175 (-2.72%)

EQRx, along with its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EQRX EQRx, Inc.
$6.27 /

-0.175 (-2.72%)

EQRX EQRx, Inc.
$6.27 /

-0.175 (-2.72%)

Earnings
Concentrix sees FY22 revenue $6.45B-$6.6B, consensus $6.16B » 18:20
01/18/22
01/18
18:20
01/18/22
18:20
CNXC

Concentrix

$164.23 /

-3.58 (-2.13%)

FY22 non-GAAP operating…

FY22 non-GAAP operating income is expected to be in the range of $890M-$930M. The effective tax rate is expected to approximate 25%-26%.

ShowHide Related Items >><<
CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

09/29/21 Barrington
Concentrix price target raised to $202 from $182 at Barrington
06/15/21 Barrington
Concentrix initiated with an Outperform at Barrington
CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

Earnings
Concentrix sees Q1 revenue 1.51B-$1.54B, consensus $1.5B » 18:18
01/18/22
01/18
18:18
01/18/22
18:18
CNXC

Concentrix

$164.23 /

-3.58 (-2.13%)

Q1 non-GAAP operating…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

09/29/21 Barrington
Concentrix price target raised to $202 from $182 at Barrington
06/15/21 Barrington
Concentrix initiated with an Outperform at Barrington
CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

Earnings
Concentrix reports Q4 adjusted EPS $2.99, consensus $2.71 » 18:17
01/18/22
01/18
18:17
01/18/22
18:17
CNXC

Concentrix

$164.23 /

-3.58 (-2.13%)

Reports Q4 revenue…

Reports Q4 revenue $1.47B, consensus $1.46B. "We delivered adjusted constant currency revenue growth above 17 percent with margin expansion in 2021, our first year as an independent public company," said Chris Caldwell, Concentrix President and CEO. "We are on track integrating the complementary PK acquisition. This further differentiates our unmatched CX capabilities and industry-leading execution. Our strong close to the year, including double-digit revenue growth, margin expansion, and strong new business signings in the fourth quarter, gives us confidence in our ability to grow above the market during 2022."

ShowHide Related Items >><<
CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

09/29/21 Barrington
Concentrix price target raised to $202 from $182 at Barrington
06/15/21 Barrington
Concentrix initiated with an Outperform at Barrington
CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

CNXC Concentrix
$164.23 /

-3.58 (-2.13%)

Hot Stocks
Ero Copper reports two separate fatal incidents at its operations » 18:05
01/18/22
01/18
18:05
01/18/22
18:05
ERO

Ero Copper

$13.20 /

+0.21 (+1.62%)

Ero Copper Corp. reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ERO Ero Copper
$13.20 /

+0.21 (+1.62%)

ERO Ero Copper
$13.20 /

+0.21 (+1.62%)

01/12/22 National Bank
Ero Copper price target lowered to C$21 from C$30 at National Bank
01/12/22 BMO Capital
Ero Copper price target lowered to C$29 from C$30 at BMO Capital
01/12/22 Canaccord
Ero Copper price target lowered to C$23.50 from C$25 at Canaccord
01/12/22 Raymond James
Ero Copper price target lowered to C$24 from C$28 at Raymond James
Hot Stocks
ImmunityBio reports results of Phase 2 pancreatic cancer trial » 18:03
01/18/22
01/18
18:03
01/18/22
18:03
IBRX

ImmunityBio

$6.21 /

-0.445 (-6.69%)

ImmunityBio announced…

ImmunityBio announced interim results in its metastatic pancreatic cancer trial showing that the overall survival rate for patients doubled compared to historical survival rate of three months after two prior lines of therapy. The data of the Phase 2 trial studying a combination immunotherapy - Nant Cancer Vaccine - also show treatment-related serious adverse events were uncommon - 8% - and no treatment-related deaths were reported. Based on these findings, ImmunityBio plans to meet with the FDA in 2022 to discuss the path for the approval of combination therapies for pancreatic cancer. The results were presented at the American Society of Clinical Oncology Gastrointestinal conference, which is being held virtually. To date, 27% of third-line or greater patients remain on study. The median overall survival in this highly advanced group of patients, who failed two to six prior lines of treatment, is 5.8 months exceeding the approximately three-month historical median overall survival. On the strength of this early data and significant unmet medical need, the company has expanded enrollment in the third-line or greater cohort.

ShowHide Related Items >><<
IBRX ImmunityBio
$6.21 /

-0.445 (-6.69%)

IBRX ImmunityBio
$6.21 /

-0.445 (-6.69%)

12/20/21 Piper Sandler
ImmunityBio price target lowered to $20 from $25 at Piper Sandler
10/19/21 Piper Sandler
Piper says ImmunityBio could have 'blockbuster opportunity' with Anktiva
06/04/21 Piper Sandler
ImmunityBio shared 'positive data points' on N-803 at ASCO, says Piper Sandler
04/07/21 Piper Sandler
ImmunityBio price target raised to $25 from $18 at Piper Sandler
IBRX ImmunityBio
$6.21 /

-0.445 (-6.69%)

IBRX ImmunityBio
$6.21 /

-0.445 (-6.69%)

Hot Stocks
SoFi Technologies gets regulatory approval to become national bank » 18:01
01/18/22
01/18
18:01
01/18/22
18:01
SOFI

SoFi Technologies

$12.04 /

-1.16 (-8.79%)

SoFi Technologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

16:48 Today Wedbush
Wedbush starts SoFi at Outperform on 'strong' growth outlook
16:16 Today Wedbush
SoFi Technologies initiated with an Outperform at Wedbush
06:55 Today Mizuho
SoFi Technologies price target lowered to $17 from $30 at Mizuho
04:48 Today Goldman Sachs
SoFi Technologies initiated with a Neutral at Goldman Sachs
SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

  • 16
    Nov
SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

SOFI SoFi Technologies
$12.04 /

-1.16 (-8.79%)

Hot Stocks
Codexis' treatment of homocystinuria granted Orphan Drug Designation by FDA » 18:00
01/18/22
01/18
18:00
01/18/22
18:00
CDXS

Codexis

$22.05 /

-1.405 (-5.99%)

Codexis announced the…

Codexis announced the U.S. Food and Drug Administration, or FDA, has granted Orphan Drug Designation to its modified version of methionine gamma-lyase enzyme from the bacterium Pseudomonas entomophila in the treatment of homocystinuria. Reference Link

ShowHide Related Items >><<
CDXS Codexis
$22.05 /

-1.405 (-5.99%)

CDXS Codexis
$22.05 /

-1.405 (-5.99%)

12/31/21 Benchmark
Pfizer COVID-19 pill approval in UK could be boost for Codexis, says Benchmark
12/22/21 Craig-Hallum
Craig-Hallum bullish on Codexis, sees potential for upside to 2022 estimates
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
CDXS Codexis
$22.05 /

-1.405 (-5.99%)

CDXS Codexis
$22.05 /

-1.405 (-5.99%)

Hot Stocks
Ellington Financial reports estimated book value per share $18.39 on December 31 » 17:57
01/18/22
01/18
17:57
01/18/22
17:57
EFC

Ellington Financial

$17.88 /

+0.185 (+1.05%)

This estimate includes…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EFC Ellington Financial
$17.88 /

+0.185 (+1.05%)

EFC Ellington Financial
$17.88 /

+0.185 (+1.05%)

06/07/21 UBS
Ellington Financial downgraded to Neutral from Buy at UBS
05/19/21 BTIG
Ellington Financial price target raised to $19 from $18.50 at BTIG
EFC Ellington Financial
$17.88 /

+0.185 (+1.05%)

  • 13
    Oct
  • 07
    Jul
Initiation
Brown-Forman initiated with a Market Perform at Bernstein » 17:47
01/18/22
01/18
17:47
01/18/22
17:47
BF.B

Brown-Forman

$66.54 /

-1.35 (-1.99%)

Bernstein analyst Nadine…

Bernstein analyst Nadine Sarwat initiated coverage of Brown-Forman with a Market Perform rating and $70 price target. The company offers a high-quality portfolio of brands in U.S. whiskey and tequila, but it is also faced with "interlinked challenges" around pricing and gross margin expansion, the analyst tells investors in a research note. Sarwat adds that while he forecasts 10.5% normalized EPS CAGR with upside to margin estimates, the stock's current valuation premium indicates that these factors are fairly priced in.

ShowHide Related Items >><<
BF.B Brown-Forman
$66.54 /

-1.35 (-1.99%)

BF.B Brown-Forman
$66.54 /

-1.35 (-1.99%)

16:26 Today Bernstein
Brown-Forman initiated with a Market Perform at Bernstein
12/09/21 Citi
Brown-Forman price target lowered to $77 from $80 at Citi
12/08/21 Barclays
Brown-Forman price target lowered to $72 from $74 at Barclays
08/26/21 UBS
Brown-Forman upgraded to Neutral from Sell at UBS
BF.B Brown-Forman
$66.54 /

-1.35 (-1.99%)

BF.B Brown-Forman
$66.54 /

-1.35 (-1.99%)

Hot Stocks
Volkswagen, Bosch sign MOU to explore forming European battery solution provider » 17:43
01/18/22
01/18
17:43
01/18/22
17:43
VWAGY

Volkswagen

$30.18 /

-1.41 (-4.46%)

The Volkswagen Group and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VWAGY Volkswagen
$30.18 /

-1.41 (-4.46%)

VWAGY Volkswagen
$30.18 /

-1.41 (-4.46%)

01/05/22 RBC Capital
Stellantis initiated with a Sector Perform at RBC Capital
12/28/21 BofA
BofA sees December U.S. light vehicle sales down 20%
12/09/21 Deutsche Bank
Volkswagen price target lowered to EUR 210 from EUR 270 at Deutsche Bank
11/29/21 Citi
Volkswagen downgraded to Neutral from Buy at Citi
VWAGY Volkswagen
$30.18 /

-1.41 (-4.46%)

VWAGY Volkswagen
$30.18 /

-1.41 (-4.46%)

VWAGY Volkswagen
$30.18 /

-1.41 (-4.46%)

Hot Stocks
United Community Banks reports Q4 operating EPS 64c, consensus 64c » 17:34
01/18/22
01/18
17:34
01/18/22
17:34
UCBI

United Community Banks

$38.50 /

-0.59 (-1.51%)

Reports Q4 revenue…

Reports Q4 revenue $175.4M, consensus $178.67M. CEO Lynn Harton stated, "We are very pleased by United's performance this quarter and in 2021. In the quarter, both loan and deposit growth were strong and noninterest income benefited from strong, but seasonally lower, mortgage production and a great SBA quarter. On the strategic front, we completed the acquisition of Aquesta Financial Holdings, Inc. and Aquesta Bank on October 1, boosting our Charlotte presence and adding the Wilmington, North Carolina market, both of which are growth markets that fit well with our footprint and culture. We also completed the operational conversion of Aquesta in mid-November, bringing the United brand to these great markets. We are proud that this outstanding team of bankers has joined us and we believe that they are a great fit for United. Finally, while not included in the quarterly results, on January 1 we completed the acquisition of Reliant Bancorp, expanding our Tennessee presence into the fast-growing Nashville MSA with a very high performance organization."

ShowHide Related Items >><<
UCBI United Community Banks
$38.50 /

-0.59 (-1.51%)

UCBI United Community Banks
$38.50 /

-0.59 (-1.51%)

07/21/21 Raymond James
United Community price target lowered to $36 from $39 at Raymond James
UCBI United Community Banks
$38.50 /

-0.59 (-1.51%)

UCBI United Community Banks
$38.50 /

-0.59 (-1.51%)

Hot Stocks
Roche awarded $340M Army contract for COVID-19 rapid antigen tests » 17:31
01/18/22
01/18
17:31
01/18/22
17:31
RHHBY

Roche

$50.03 /

-0.27 (-0.54%)

Roche was awarded a $340M…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$50.03 /

-0.27 (-0.54%)

RHHBY Roche
$50.03 /

-0.27 (-0.54%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/04/22 JPMorgan
Roche price target raised to CHF 390 from CHF 360 at JPMorgan
12/22/21 Citi
Roche resumed with a Buy at Citi
12/13/21 Credit Suisse
Roche price target raised to CHF 370 from CHF 350 at Credit Suisse
RHHBY Roche
$50.03 /

-0.27 (-0.54%)

RHHBY Roche
$50.03 /

-0.27 (-0.54%)

RHHBY Roche
$50.03 /

-0.27 (-0.54%)

Recommendations
Coca-Cola HBC price target raised to 3,260 GBp from 3,200 GBp at Deutsche Bank » 17:30
01/18/22
01/18
17:30
01/18/22
17:30
CCHGY

Coca-Cola HBC

$36.05 /

-0.135 (-0.37%)

Deutsche Bank analyst…

Deutsche Bank analyst Gerry Gallagher raised the firm's price target on Coca-Cola HBC to 3,260 GBp from 3,200 GBp and keeps a Buy rating on the shares.

ShowHide Related Items >><<
CCHGY Coca-Cola HBC
$36.05 /

-0.135 (-0.37%)

11/30/21 JPMorgan
Coca-Cola HBC upgraded to Overweight from Neutral at JPMorgan
11/04/21 Barclays
Coca-Cola HBC price target raised to 3,000 GBp from 2,900 GBp at Barclays
10/13/21 Deutsche Bank
Coca-Cola HBC price target raised to 3,185 GBp from 3,100 GBp at Deutsche Bank
10/13/21 JPMorgan
Coca-Cola HBC price target lowered to 2,725 GBp from 2,850 GBp at JPMorgan
Hot Stocks
AstraZeneca's TOPAZ-1 trial of Imfinzi shows reduced risk of death in BTC » 17:30
01/18/22
01/18
17:30
01/18/22
17:30
AZN

AstraZeneca

$59.83 /

+0.98 (+1.67%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$59.83 /

+0.98 (+1.67%)

AZN AstraZeneca
$59.83 /

+0.98 (+1.67%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
AZN AstraZeneca
$59.83 /

+0.98 (+1.67%)

AZN AstraZeneca
$59.83 /

+0.98 (+1.67%)

AZN AstraZeneca
$59.83 /

+0.98 (+1.67%)

AZN AstraZeneca
$59.83 /

+0.98 (+1.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.